Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 9/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.49 |
| ▸ | NPY1R | P25929 | 7/20 | 0.49 |
| ▸ | NPY2R | P49146 | 5/20 | 0.46 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | TFPI | P10646 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30265523 | 0.91 | NPY4R (0.54) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30264923 | 0.91 | NPY4R (0.54) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL31433247 | 0.91 | NPY4R (0.59) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL31433365 | 0.90 | TFPI (0.54) | NPY4RNPY5RNPY1RNPY2RIL23R | |
| SCHEMBL30264953 | 0.88 | NPY4R (0.51) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30265009 | 0.88 | NPY4R (0.58) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30866924 | 0.87 | NPY4R (0.56) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29743134 | 0.87 | IL23R (0.51) | NPY4RNPY5RNPY1RNPY2RIL23R | |
| SCHEMBL30264901 | 0.87 | FNTA (0.52) | NPY4RNPY5RNPY1RNPY2ROPRM1 | |
| SCHEMBL31433292 | 0.86 | NPY4R (0.55) | NPY4RNPY5RNPY1RNPY2RIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12103951-B2 | Use of CGRP receptor antagonists in neuroprotection and neurological disorders | SOARES CHRISTOPHER JOSEPH (US) | 2024-10-01 | — | — | US | disclosed |
| EP-4316595-A2 | USE OF CGRP RECEPTOR ANTAGONISTS IN TREATING GLAUCOMA | Soares, Christopher, J. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-3506925-B1 | USE OF CGRP RECEPTOR ANTAGONISTS IN TREATING GLAUCOMA | SOARES CHRISTOPHER J (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230212248-A1 | USE OF CGRP RECEPTOR ANTAGONISTS IN NEUROPROTECTION AND NEUROLOGICAL DISORDERS | SOARES CHRISTOPHER JOSEPH (US) | 2023-07-06 | — | — | US | disclosed |
| US-11390654-B2 | Use of CGRP receptor antagonists in neuroprotection and neurological disorders | SOARES CHRISTOPHER JOSEPH (US) | 2022-07-19 | — | — | US | disclosed |